menu
    • menu

    Company profile for Grace Science

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Grace was born in 2009 with a rare, debilitating disease. Deep in confusion and grief, Kristen and Matt Wilsey were faced with three options: Go home and simply enjoy their daughter. To them, this was akin to “giving up”. Focus 100% on improving the quality of Grace’s daily life through therapy. Find a cure themselves. They went with option 3 and set out to find a cure. After receiving Grace’s diagnosis in 2013, Ma...
    Grace was born in 2009 with a rare, debilitating disease. Deep in confusion and grief, Kristen and Matt Wilsey were faced with three options: Go home and simply enjoy their daughter. To them, this was akin to “giving up”. Focus 100% on improving the quality of Grace’s daily life through therapy. Find a cure themselves. They went with option 3 and set out to find a cure. After receiving Grace’s diagnosis in 2013, Matt and Kristen established the Grace Science Foundation to fund research by premier labs around the world to better understand NGLY1 Deficiency. This research rapidly produced numerous insights into the disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Grace ScienceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1142 Crane Street, Ste 4 Menlo Park, CA 94025
    Telephone
    Telephone
    1 (415) 985-6211
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://gracesciencellc.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/grace-science-llc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/gracesciencellc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA picks Denali, Neurogene and more for rare disease program
    FDA picks Denali, Neurogene and more for rare disease program

    04 Jun 2024

    // Helen Floersh FIERCE BIOTECH

    https://www.fiercebiotech.com/research/fda-selects-denali-neurogene-larimar-and-grace-sciences-rare-disease-therapy-pilot

    Helen Floersh FIERCE BIOTECH
    04 Jun 2024
    Share Share
    Grace Science, FDA START For NGLY1 Gene Therapy GS-100, 2nd Patient Treated
    Grace Science, FDA START For NGLY1 Gene Therapy GS-100, 2nd Patient Treated

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603258576/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    Grace Science Announces First Patient Treated in Phase 1/2/3 Trial of GS-100
    Grace Science Announces First Patient Treated in Phase 1/2/3 Trial of GS-100

    05 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240304132147/en

    BUSINESSWIRE
    05 Mar 2024
    Share Share
    Grace Announces Clearance of IND to Initiate a Phase 1/2/3 Trial of AAV9 NGLY1
    Grace Announces Clearance of IND to Initiate a Phase 1/2/3 Trial of AAV9 NGLY1

    07 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231106501186/en

    BUSINESSWIRE
    07 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search